GlassScriptPhysician profile
Ajoy Kapoor
NPI 1265414395
$6,025.49
in general payments reported to CMS, 2019-2025
29 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $176 · 2021: $148 · 2022: $305 · 2023: $1,462 · 2024: $1,651 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,512 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,512.49 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,080.74 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $701.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $548.04 | 2022-2025 | Verquvo, Capvaxive, Lagevrio |
| Amgen INC. | $468.14 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $389.18 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $317.17 | 2019-2025 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $298.09 | 2024 | Arcalyst |
| Pfizer INC. | $278.56 | 2019-2025 | |
| Novo Nordisk INC | $271.98 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $213.86 | 2019-2024 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.52 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $172.52 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $137.56 | 2024-2025 | Opsumit, Uptravi |
| Lexicon Pharmaceuticals, INC. | $119.47 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $117.42 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $113.14 | 2023 | Arcalyst |
| Janssen Pharmaceuticals, INC | $109.42 | 2019-2020 | |
| Inspire Medical Systems, INC. | $104.66 | 2024-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $75.55 | 2023 | |
| Scpharmaceuticals INC. | $55.72 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $41.10 | 2019-2023 | Livalo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.75 | 2019-2024 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $38.53 | 2019 | |
| Boston Scientific Corporation | $33.89 | 2024 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $23.24 | 2023 | Onpattro |
| Amryt Pharma Holdings LTD | $22.00 | 2021 | |
| Preventice Services, LLC | $20.56 | 2019 | |
| Glaxosmithkline, LLC. | $17.14 | 2025 | Arexvy, Shingrix |
| Impulse Dynamics (USA) INC. | $16.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajoy Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.